lupus

News

AZ's bid for Fasenra approval in COPD falls short

AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.

News

Person holds their hand, radiating pain from the palm.

Data at EULAR back Biogen, UCB's first-in-class lupus drug

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

News

football going into the net past goalkeeper to score

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of

News

Viatris splashes out $350m on pair of Idorsia therapies

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus

News

Gilead adds lupus, arthritis therapies with EVOQ alliance

US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<

News

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupu

AZ's bid for Fasenra approval in COPD falls short

Data at EULAR back Biogen, UCB's first-in-class lupus drug

UCB, Biogen lupus drug scores in phase 3 trial

Viatris splashes out $350m on pair of Idorsia therapies

Gilead adds lupus, arthritis therapies with EVOQ alliance

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

lupus

Editor's Picks